AVITA Medical, Inc. (RCEL) Misses Q1 EPS by 41c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
BofA Securities Reiterates Buy Rating on Avita Medical Ltd. (RCEL)
May 14, 2024 8:48 AM EDTBofA Securities analyst Lyanne Harrison reiterated a Buy rating and $21.00 price target on Avita Medical Ltd. (NASDAQ: RCEL).
The analyst comments "We reiterate our Buy; PO unchanged at US$21/A$6. We expect AVITA will gain momentum as the year progresses, driven by short term... More
